Leerink Partnrs Issues Negative Estimate for Sanofi Earnings

Sanofi (NASDAQ:SNY - Free Report) - Stock analysts at Leerink Partnrs lowered their Q2 2025 earnings estimates for shares of Sanofi in a report issued on Monday, July 7th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $0.94 for the quarter, down from their prior forecast of $0.99. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's FY2025 earnings at $4.53 EPS, FY2026 earnings at $4.96 EPS, FY2027 earnings at $5.08 EPS, FY2028 earnings at $5.48 EPS and FY2029 earnings at $6.01 EPS.

A number of other equities analysts also recently weighed in on the company. Morgan Stanley set a $56.00 price target on Sanofi in a research report on Monday, June 2nd. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. BNP Paribas started coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $61.50.

Sanofi Stock Up 1.3%

Shares of SNY traded up $0.65 on Wednesday, hitting $48.83. The company's stock had a trading volume of 2,308,244 shares, compared to its average volume of 2,337,425. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The firm's fifty day moving average price is $50.41 and its 200-day moving average price is $52.09. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The firm has a market capitalization of $119.75 billion, a price-to-earnings ratio of 17.44, a P/E/G ratio of 1.05 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. The firm had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company's quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.78 EPS.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were given a dividend of $2.0369 per share. This represents a yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date was Friday, May 9th. Sanofi's payout ratio is 57.14%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Dynamic Advisor Solutions LLC increased its position in Sanofi by 4.5% during the 2nd quarter. Dynamic Advisor Solutions LLC now owns 58,352 shares of the company's stock worth $2,819,000 after buying an additional 2,515 shares during the period. Bruce G. Allen Investments LLC increased its position in Sanofi by 4.9% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 5,476 shares of the company's stock worth $265,000 after buying an additional 257 shares during the period. Sunpointe LLC increased its position in Sanofi by 19.3% during the 2nd quarter. Sunpointe LLC now owns 6,409 shares of the company's stock worth $310,000 after buying an additional 1,035 shares during the period. Berkshire Bank increased its position in Sanofi by 10.8% during the 2nd quarter. Berkshire Bank now owns 5,602 shares of the company's stock worth $271,000 after buying an additional 546 shares during the period. Finally, Fiduciary Alliance LLC increased its position in Sanofi by 42.4% during the 2nd quarter. Fiduciary Alliance LLC now owns 5,250 shares of the company's stock worth $254,000 after buying an additional 1,562 shares during the period. Institutional investors own 14.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.